Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Effects of postoperative fluids beyond the first 24 h.
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
27
06
2023
received:
12
02
2023
accepted:
16
07
2023
pubmed:
31
7
2023
medline:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
There are no guidelines for intravenous fluid (IVF) administration after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This study assessed rates of post-CRS/HIPEC morbidity according to perioperative IVF administration. All patients undergoing CRS/HIPEC March 2007 to June 2018 were reviewed, recording clinicopathologic, operative, and postoperative variables. Patients were divided by peritoneal cancer index (PCI), comparing IVF volumes and types administered intraoperatively and during the first 72 h postoperatively. Optimal IVF rate cutoffs calculated using area under the receiver operating characteristic curves and Youden's index determined associations with complications. Overall, 185 patients underwent CRS/HIPEC, and 81 (51%) had low PCI (<10) and 77 (49%) had high PCI (≥10). In low-PCI patients, high IVF rates on postoperative days (POD) #0-2 were associated with higher overall complications: POD#0 (46% vs. 89%, p = 0.001), POD#1 (40% vs. 86%, p < 0.05), and POD#2 (42% vs. 72%, p < 0.05). High IVF rates were associated with respiratory distress (7% vs. 26%, p = 0.02) on POD#0, ileus (14% vs. 47%, p = 0.007) and intensive care unit stay (11% vs. 33%, p = 0.022) on POD#1, and ICU stay (8% vs. 33%, p = 0.003) on POD#2. For low PCI patients undergoing CRS/HIPEC, higher IVF rates were associated with postoperative complications. Post-CRS/HIPEC, IVF rates should be limited to prevent morbidity.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
There are no guidelines for intravenous fluid (IVF) administration after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This study assessed rates of post-CRS/HIPEC morbidity according to perioperative IVF administration.
METHODS
METHODS
All patients undergoing CRS/HIPEC March 2007 to June 2018 were reviewed, recording clinicopathologic, operative, and postoperative variables. Patients were divided by peritoneal cancer index (PCI), comparing IVF volumes and types administered intraoperatively and during the first 72 h postoperatively. Optimal IVF rate cutoffs calculated using area under the receiver operating characteristic curves and Youden's index determined associations with complications.
RESULTS
RESULTS
Overall, 185 patients underwent CRS/HIPEC, and 81 (51%) had low PCI (<10) and 77 (49%) had high PCI (≥10). In low-PCI patients, high IVF rates on postoperative days (POD) #0-2 were associated with higher overall complications: POD#0 (46% vs. 89%, p = 0.001), POD#1 (40% vs. 86%, p < 0.05), and POD#2 (42% vs. 72%, p < 0.05). High IVF rates were associated with respiratory distress (7% vs. 26%, p = 0.02) on POD#0, ileus (14% vs. 47%, p = 0.007) and intensive care unit stay (11% vs. 33%, p = 0.022) on POD#1, and ICU stay (8% vs. 33%, p = 0.003) on POD#2.
CONCLUSIONS
CONCLUSIONS
For low PCI patients undergoing CRS/HIPEC, higher IVF rates were associated with postoperative complications. Post-CRS/HIPEC, IVF rates should be limited to prevent morbidity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133-1140Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Kapoor S, Bassily-Marcus A, Yunen RA, et al. Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. World J Crit Care Med. 2017;6(2):116.
Kuncewitch M, Levine E, Shen P, Votanopoulos K. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal tumors and colorectal adenocarcinomas. Clin Colon Rectal Surg. 2018;31(05):288-294.
Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res. 2018;7(5):599-608.
Sugarbaker PH. Peritoneal metastases, a frontier for progress. Surg Oncol Clin N Am. 2018;27(3):413-424.
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol (EJSO). 2015;41(12):1578-1589.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-3743.
Mehta SS, Gelli M, Agarwal D, Goéré D. Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases. Indian J Surg Oncol. 2016;7(7):225-229.
Blakely AM, Lee B. Complications of cytoreductive surgery and HIPEC. In: Fong Y, Gamblin T, Han E, Lee B, Zager J, eds. Cancer Regional Therapy. Springer; 2020:179-188.
Hendrix RJ, Damle A, Williams C, et al. Restrictive intraoperative fluid therapy is associated with decreased morbidity and length of stay following hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol. 2019;26(2):490-496.
Hurst D, Owusu-Agyemang P. Perioperative management of the oncologic patient undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). In: Oncologic Critical Care. Springer International Publishing; 2019:1783-1791.
Gustafsson UO, Scott MJ, Hubner M, et al. Guidelines for perioperative care in elective colorectal surgery: enhanced recovery after surgery (ERAS®) society recommendations: 2018. World J Surg 2018 433. 2018;43(3):659-695.
Mortensen K, Nilsson M, Slim K, et al. Consensus guidelines for enhanced recovery after gastrectomy. Br J Surg. 2014;101(10):1209-1229.
Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in gynecologic/oncology: enhanced recovery after surgery (ERAS) society recommendations-2019 update. Int J Gynecol Cancer. 2019;29:651-668.
Khalaf N, Ying J, Mittal S, et al. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol. 2017;15(2):273-281.
Melloul E, Hübner M, Scott M, et al. Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations. World J Surg. 2016;40(10):2425-2440.
Stenberg E, dos Reis Falcão LF, O'Kane M, et al. Guidelines for perioperative care in bariatric surgery: enhanced recovery after surgery (ERAS) society recommendations: a 2021 update. World J Surg. 2022;46(4):729-751.
Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations-part I: preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292-2310.
Jia FJ, Yan QY, Sun Q, Tuxun T, Liu H, Shao L. Liberal versus restrictive fluid management in abdominal surgery: a meta-analysis. Surg Today. 2017;47(3):344-356.
Simpson R, Quayle J, Stylianides N, Carlson G, Soop M. Intravenous fluid and electrolyte administration in elective gastrointestinal surgery: mechanisms of excessive therapy. Annals Royal Coll Surg England. 2017;99(6):497-503.
Miller TE, Mythen M, Shaw AD, et al. Association between perioperative fluid management and patient outcomes: a multicentre retrospective study. Br J Anaesth. 2021;126(3):720-729.
Jacquet P, Sugarbaker P. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
Pellegrini C, Wetter LA, Patti M, et al. Thoracoscopic esophagomyotomy initial experience with a new approach for the treatment of achalasia. Ann Surg. 1992;216(3):291-299.
Dindo D. The Clavien-Dindo classification of surgical complications. In: Cuesta M, Bonjer H, eds. Treatment of Postoperative Complications After Digestive Surgery. Springer; 2014:13-17.
Tabrizian P, Shrager B, Jibara G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18(5):1024-1031.
Lassen K. Consensus review of optimal perioperative care in colorectal surgery: enhanced recovery after surgery (ERAS) group recommendations. AArch Surg. 2009;144(10):961-969.
Myles P, Bellomo R, Corcoran T, et al. Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF): rationale and design for a multicentre randomised trial. BMJ Open. 2017;7(3):e015358.
Raspé C, Flöther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol (EJSO). 2017;43(6):1013-1027.
Thanigaimani K, Mohamed F, Cecil T, Moran BJ, Bell J. The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy. Colorectal Dis. 2013;15(12):1537-1542.
Eng OS, Dumitra S, O'Leary M, et al. Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. JAMA Surg. 2017;152(12):1156-1160.
Zhu A, Agarwala A, Bao X. Perioperative fluid management in the enhanced recovery after surgery (ERAS) pathway. Clin Colon Rectal Surg. 2019;32(2):114-120.
Pignot G, Brun C, Tourret M, et al. Essential elements of anaesthesia practice in ERAS programs. World J Urol. 2022;40(6):1299-1309.
Shamavonian R, McLachlan R, Fisher OM, et al. The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2019;10(2):235-243.
Solanki S, Mukherjee S, Agarwal V, et al. Society of onco-anaesthesia and perioperative care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Indian J Anaesth. 2019;63(12):972.
Fields AC, Divino CM. Surgical outcomes in patients with chronic obstructive pulmonary disease undergoing abdominal operations: an analysis of 331,425 patients. Surgery. 2016;159(4):1210-1216.
Kim TH, Lee JS, Lee SW, Oh YM. Pulmonary complications after abdominal surgery in patients with mild-to-moderate chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulm Dis. 2016;11(1):2785-2796.
Sullivan BJ, Bekhor EY, Carpiniello M, et al. Diaphragmatic peritoneal stripping versus full-thickness resection in CRS/HIPEC: is there a difference? Ann Surg Oncol. 2020;27(1):250-258.